Taxanes: Impact on breast cancer therapy

Lohith S. Bachegowda, Della F. Makower, Joseph A. Sparano

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Taxanes play an important role in the management of early-stage and advanced-stage breast cancer. Initial studies sought to determine whether there was antitumor activity in patients with metastatic disease, and identify the optimal agent, dose, and schedule. Subsequent studies established a role for both paclitaxel and docetaxel as adjuvant therapy, determined whether they should be administered concurrently or sequentially with other cytotoxic agents, and also determined the optimal agent, dose, and schedule. Taxanes have also been combined with biologic agents, including anti-HER2-directed therapy and antiangiogenic therapy. The aim of this article is to provide a review of pivotal trials evaluating taxane therapy that have informed the current approach for the useof taxanes in early-stage and advanced-stage breast cancer.

Original languageEnglish (US)
Pages (from-to)512-521
Number of pages10
JournalAnti-Cancer Drugs
Issue number5
StatePublished - Jun 2014


  • breast cancer
  • chemotherapy
  • taxane

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research


Dive into the research topics of 'Taxanes: Impact on breast cancer therapy'. Together they form a unique fingerprint.

Cite this